6.
Chung W, Erion K, Florez J, Hattersley A, Hivert M, Lee C
. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43(7):1617-1635.
PMC: 7305007.
DOI: 10.2337/dci20-0022.
View
7.
Zhang H, Colclough K, Gloyn A, Pollin T
. Monogenic diabetes: a gateway to precision medicine in diabetes. J Clin Invest. 2021; 131(3).
PMC: 7843214.
DOI: 10.1172/JCI142244.
View
8.
Beucher A, Miguel-Escalada I, Balboa D, De Vas M, Maestro M, Garcia-Hurtado J
. The HASTER lncRNA promoter is a cis-acting transcriptional stabilizer of HNF1A. Nat Cell Biol. 2022; 24(10):1528-1540.
PMC: 9586874.
DOI: 10.1038/s41556-022-00996-8.
View
9.
Rodenburg R
. The functional genomics laboratory: functional validation of genetic variants. J Inherit Metab Dis. 2018; 41(3):297-307.
PMC: 5959958.
DOI: 10.1007/s10545-018-0146-7.
View
10.
Bjorkhaug L, Ye H, Horikawa Y, Sovik O, Molven A, Njolstad P
. MODY associated with two novel hepatocyte nuclear factor-1alpha loss-of-function mutations (P112L and Q466X). Biochem Biophys Res Commun. 2001; 279(3):792-8.
DOI: 10.1006/bbrc.2000.4024.
View
11.
Pearson E, Boj S, Steele A, Barrett T, Stals K, Shield J
. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007; 4(4):e118.
PMC: 1845156.
DOI: 10.1371/journal.pmed.0040118.
View
12.
Wirsing A, Johnstone K, Harries L, Ellard S, Ryffel G, Stanik J
. Novel monogenic diabetes mutations in the P2 promoter of the HNF4A gene are associated with impaired function in vitro. Diabet Med. 2010; 27(6):631-5.
DOI: 10.1111/j.1464-5491.2010.03003.x.
View
13.
Steinhaus R, Robinson P, Seelow D
. FABIAN-variant: predicting the effects of DNA variants on transcription factor binding. Nucleic Acids Res. 2022; 50(W1):W322-W329.
PMC: 9252790.
DOI: 10.1093/nar/gkac393.
View
14.
Pearson E, Starkey B, Powell R, Gribble F, Clark P, Hattersley A
. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003; 362(9392):1275-81.
DOI: 10.1016/S0140-6736(03)14571-0.
View
15.
Furuta H, Iwasaki N, Oda N, Hinokio Y, Horikawa Y, Yamagata K
. Organization and partial sequence of the hepatocyte nuclear factor-4 alpha/MODY1 gene and identification of a missense mutation, R127W, in a Japanese family with MODY. Diabetes. 1997; 46(10):1652-7.
DOI: 10.2337/diacare.46.10.1652.
View
16.
Soutoglou E, Papafotiou G, Katrakili N, Talianidis I
. Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins. J Biol Chem. 2000; 275(17):12515-20.
DOI: 10.1074/jbc.275.17.12515.
View
17.
Krois A, Dyson H, Wright P
. Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci U S A. 2018; 115(48):E11302-E11310.
PMC: 6275486.
DOI: 10.1073/pnas.1814051115.
View
18.
Thomas H, Jaschkowitz K, Bulman M, Frayling T, Mitchell S, Roosen S
. A distant upstream promoter of the HNF-4alpha gene connects the transcription factors involved in maturity-onset diabetes of the young. Hum Mol Genet. 2001; 10(19):2089-97.
DOI: 10.1093/hmg/10.19.2089.
View
19.
Raeder H, Bjorkhaug L, Johansson S, Mangseth K, Sagen J, Hunting A
. A hepatocyte nuclear factor-4 alpha gene (HNF4A) P2 promoter haplotype linked with late-onset diabetes: studies of HNF4A variants in the Norwegian MODY registry. Diabetes. 2006; 55(6):1899-903.
DOI: 10.2337/db05-1677.
View
20.
Chen V, Arendall 3rd W, Headd J, Keedy D, Immormino R, Kapral G
. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):12-21.
PMC: 2803126.
DOI: 10.1107/S0907444909042073.
View